DuChemBIO Co., Ltd.
KKRX:1767507,720.00
KRW
-700.00
(-8.31%)
ISIN
KR7176750008
Return %
Stock
S&P 500
1Y
-18.31
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Woo Kim
- Full Time Employees
- 144
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seoul South Korea
- IPO Date
- Dec 29, 2014
- Website
- duchembio.com
- Similar Companies
- Business
- DuChemBio Co., Ltd. is a South Korea-based radiopharmaceutical company that specializes in the development, manufacturing, and commercialization of precision diagnostic radiopharmaceuticals, therapeutic radioligands, and automated radiopharmaceutical equipment. Founded in 2002 and headquartered in Seoul, Republic of Korea, the company operates the largest commercial radiopharmaceutical manufacturing and distribution network in South Korea, comprising multiple Good Manufacturing Practice (GMP)-certified cyclotron facilities nationwide. DuChemBio serves tertiary hospitals, specialized oncology and neurology clinics, nuclear medicine departments, and research institutions domestically and across broader Asia-Pacific markets. The company's offerings are organized into three primary business divisions: Diagnostic Radiopharmaceuticals, Radiopharmaceutical CDMO and Therapeutics, and Medical Equipment. Its diagnostic portfolio comprises [18F] FP-CIT (Dopaceq), a positron emission tomography (PET) tracer designed for the early detection and differential diagnosis of Parkinson's disease and related Parkinsonian syndromes; Neuraceq (Florbetaben 18F) and Vizamyl (Flutemetamol 18F), targeted amyloid PET imaging agents used to evaluate beta-amyloid neuritic plaque density in the brains of patients with suspected Alzheimer's disease and cognitive impairment; PROSTASEEK (18F-flotufolastat), a prostate-specific membrane antigen (PSMA)-targeted PET imaging radiopharmaceutical indicated for identifying PSMA-positive lesions in patients with prostate cancer; 18F-FDG (fluorodeoxyglucose), a standard metabolic PET imaging agent utilized in oncology, neurology, and cardiology; and 18F-FDOPA (L-DOPA), employed in the assessment of neuroendocrine tumors, pheochromocytomas, and central nervous system lesions. Within its CDMO and therapeutic business, DuChemBio provides comprehensive contract development and manufacturing organization services, radiolabeling, radioisotope synthesis, active pharmaceutical ingredient (API) production, and clinical development for radioligand therapies targeting novel oncological markers such as FAP and TROP2. In its equipment unit, the company manufactures and distributes automated dispensing and radiation management systems, including the PARTIO VS automated distribution system for PET radiopharmaceuticals. In recent corporate developments, DuChemBio completed its listing transfer to the KOSDAQ market (KRX: 176750) to support capital expansion and global growth initiatives. The company merged with its radiopharmaceutical CDMO subsidiary, Radio D&S Labs, to consolidate contract manufacturing capabilities and integrate specialized radiochemistry expertise. DuChemBio also committed a KRW 34.3 billion capital investment to construct a dedicated radiopharmaceutical CDMO and R&D production facility in Jeongeup, South Korea, to scale therapeutic radiopharmaceutical manufacturing and radioisotope processing. Furthermore, the company broadened its international presence through exclusive out-licensing agreements for its Parkinson's diagnostic tracer 18F-FP-CIT across Taiwan and multiple Southeast Asian jurisdictions, while securing domestic regulatory approvals and advancing commercial alliances for its oncology imaging portfolio.